血小板和内皮细胞黏附分子1表达水平和免疫浸润与肺腺癌预后的关系  

Platelet and endothelial cell adhesion molecule 1 is a prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma

作　　者：叶贯超 刘亚飞[1] 黄岚[2] 张春敭[1] 盛银良 吴彬[1] 韩露[1] 董博 吴春莉 齐宇 Ye Guanchao;Liu Yafei;Huang Lan;Zhang Chunyang;Sheng Yinliang;Wu Bin;Han Lu;Dong Bo;Wu Chunli;Qi Yu(Department of Thoracic Surgery,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Biotherapy Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院胸外科,450052 [2]郑州大学第一附属医院生物治疗中心,450052

出　　处：《中华实验外科杂志》2020年第8期1527-1530,共4页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(81773045)。

摘　　要：目的探讨血小板和内皮细胞黏附分子1(PECAM1)表达水平和免疫浸润与肺腺癌预后的关系。方法从基因表达数据库(GEO)下载3个肺腺癌数据集验证PECAM1在肺腺癌与正常肺组织中的差异表达。收集2019年9月至2020年1月郑州大学第一附属医院胸外科的肺腺癌手术标本36例,采用实时定量反转录聚合酶链反应(RT-qPCR)验证PECAM1在肺腺癌与正常肺组织中的差异表达。通过免疫组织化学(IHC)染色数据分析人类蛋白质图谱(HPA)数据库中肺腺癌组织与正常肺组织中PECAM1蛋白水平的表达。下载癌症基因组图谱(TCGA)数据库中肺腺癌患者临床数据,利用Kaplan-Meier法分析PECAM1表达与肺腺癌总生存时间的相关性,利用单因素和多因素COX回归分析PECAM1是否可以作为肺腺癌预后分析的独立分子标志物。通过肿瘤免疫评估资源(TIMER)在肺腺癌样本数据上评估,确定PECAM1表达与免疫浸润之间的相关性,评估PECAM1表达与肿瘤浸润免疫细胞的基因标志物之间的相关性。结果在GSE40791(t=23.550,P<0.01)、GSE32863(t=27.960,P<0.01)和GSE75037(t=23.440,P<0.01)数据集中,PECAM1在肺腺癌中的表达水平明显低于正常组织。同时RT-qPCR验证PECAM1在肺腺癌标本中的表达明显低于对应的正常组织(t=5.410,P<0.01)。HPA蛋白质表达数据表明肺腺癌组织中未检测到PECAM1的蛋白表达,正常肺组织为中表达。单因素COX回归分析得出PECAM1的表达[风险比(HR),0.634;95%可信区间(CI),0.473~0.874,P<0.01]、肿瘤大小(HR,2.295;95%CI,1.554~3.388,P<0.01)、淋巴结转移(HR,2.468;95%CI,1.830~3.328,P<0.01)、远处转移(HR,1.926;95%CI,1.086~3.416,P<0.05)和临床分期(HR,2.446;95%CI,1.778~3.363,P<0.01)都为肺腺癌患者不良预后的预测因素。多因素分析显示,PECAM1的表达(HR,0.704;95%CI,0.518~0.957,P<0.05)可以作为肺腺癌患者预后的独立分子标志物。TIMER数据库分析发现PECAM1的表达与免疫浸润细胞及其标记基因之间明�Objective To analyze the relationship between a prognostic-related biomarker-platelet and endothelial cell adhesion molecule 1(PECAM-1)and immune infiltrates in lung adenocarcinoma.Methods Download 3 datasets from GEO database to verify the differential expression of PECAM-1 in lung adenocarcinoma and normal lung tissues.36 pairs of lung adenocarcinoma tissues and corresponding adjacent nontumorous tissues were obtained from the First Affiliated Hospital of Zhengzhou University between September 2019 and January 2020.Real-time quantitative reverse transcriptase-polymerase chain reaction(RT-qPCR)was used to verify the differential expression of PECAM-1 in lung adenocarcinoma and normal lung tissues.The protein levels of PECAM1 expression in lung adenocarcinoma samples and normal lung samples from the HPA database were analyzed by the immunohistochemistry(IHC)staining data.The clinical data of lung adenocarcinoma patients was downloaded in the TCGA database,the Kaplan-Meier method was used to analyze the correlation between the expression of PECAM-1 and the overall survival in lung adenocarcinoma,univariate and multivariate COX regression were used to analyze whether PECAM-1 can be used as lung adenocarcinoma independent molecular markers for prognostic analysis.These infiltrates were assessed using Tumor Immune Estimation Resource(TIMER)on lung adenocarcinoma sample data,and the correlation between PECAM1 expression and immune infiltration was determined.Results In GSE40791(t=23.550,P<0.01),GSE32863(t=27.960,P<0.01)and GSE75037(t=23.440,P<0.01),the PECAM1 mRNA levels in lung adenocarcinoma tissues were significantly lower than those in normal lung tissues.In addition,RT-qPCR was used to evaluate the expression of PECAM1,which was significantly lower in lung adenocarcinoma compared with adjacent nontumor tissues(t=5.410,P<0.01).Based on the protein expression data from the HPA,it was further confirmed that PECAM1 protein was lowlier expressed in lung adenocarcinoma than in normal lung tissues.Univariate analysis sh

关 键 词：血小板和内皮细胞黏附分子1 肺腺癌 预后 免疫浸润 

分 类 号：R734.2[医药卫生—肿瘤]